Business Of Biotech

Business Of Biotech

Ben Comer
Country USA
Language EN
Episodes 315
Latest 16.11.2026

The Business of Biotech is a podcast dedicated to leaders of emerging biopharma firms. It provides insights into organizational, finance, HR, clinical, manufacturing, regulatory, and commercial challenges faced when navigating a company from idea to success. Each episode features guest commentary and best practices from accomplished founders and industry luminaries. The podcast is produced by Life Science Connect.

Episodes

  • Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.
    Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D. 16.11.2026 55m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA's Fast Track and RMAT designations aided commu...
  • Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
    Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley 09.11.2026 50m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matte...
  • Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.
    Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D. 02.11.2026 53m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the lead...
  • Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy
    Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy 26.10.2026 56m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Keith Murphy, CEO at Viscient Biosciences, unpacks how 3D human tissue models and scaffold-free bioprinting can change the way developers predict drug safety and model disease. Keith traces his professional journey from MIT and Amgen, to founding Organovo and building Viscient and VivoSim (formerly Organovo) into companies that push New Approach Methodologies (NAM) adoption and smarter, ...
  • Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.
    Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D. 19.10.2026 47m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and biotech investing. Bret reflects on lessons he learned at Alnylam about the power of genetically validated drug targets and the importance of team culture, why CNS drug development fails so often, and the problem with animal models. He also tal...
  • AI, China, And Biotech Investing With SR One's Simeon George, M.D.
    AI, China, And Biotech Investing With SR One's Simeon George, M.D. 12.10.2026 49m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets, and the good and bad signs that emerge during diligence. Simeon also discusses a new report published by SR One on how AI and China are changing the strategy and playbook for new drug creation. Access this and hundreds of epi...
  • Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding
    Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding 05.10.2026 59m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign weal...
  • Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.
    Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D. 28.09.2026 55m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why radiopharmaceutical companies live or die by manufacturing. Philina talks about AdvanCell's recent oversubscribed $315 million Series D raise, the company's vertically integrated manufacturing capability, and future plans for a regional U.S. man...
  • Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.
    Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D. 21.09.2026 46m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk’s adipose-targeted siRNA strategy, the genetics-driven logic behind its targets, and what it takes to fund and build a clinical-stage company. Alex also discusses Moonwalk's recent $70 million Series B raise, using AI to prioritize targets and improve siRNA...
  • Biotech Finance And Investor Update With Independent Board Director Allan Shaw
    Biotech Finance And Investor Update With Independent Board Director Allan Shaw 14.09.2026 55m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the strategies needed to secure capital now. Allan explains how biotech investors price risk as the market opens back up, the importance of valuation discipline, and the financing choices that separate “available capital” from “accessible capital.” Alla...
  • Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
    Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig 07.09.2026 55m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today’s funding environment and what it takes to build a lean virtual drug development company without institutional financing. Craig describes practical financing paths, hard truths about costs, and the tradeoffs that make a rare disease program investable through alternative ...
  • Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka
    Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka 31.08.2026 58m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the moments when biology and execution punch back. Olivia also discusses a collaborative effort in Europe to create a stronger public market and investor base, and what the emergence of AI and Chinese biotech means for building tomorrow's biotec...
  • Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil
    Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil 24.08.2026 56m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and early-stage biotech companies with a focus on clinical data and differentiation as the key value drivers. Omar talks about his interest in 'undruggable targets,' what's happening with the IPO market, an investor shift from biology risk to commercial risk, and building companies through a ve...
  • Getting To A First Product Approval With Celcuity's Brian Sullivan
    Getting To A First Product Approval With Celcuity's Brian Sullivan 17.08.2026 50m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, and why targeting an “untreated disease mechanism” can beat chasing a single mutation. Brian also discusses the process for licensing a shelved Pfizer asset for development, designing Phase 3 trials that challenge assumptions, the benefits of...
  • Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings
    Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings 10.08.2026 50m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Paul is candid about problems with clinical trial infrastructure in the U.S., what it will take to fix trial access (biotechs should actively facilitate patient access to trials and work with community health center...
  • A Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D.
    A Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D. 03.08.2026 55m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Annette Bakker, Ph.D., CEO at the Children's Tumor Foundation, and Andrew Lo, Ph.D., Finance Professor at MIT's Sloan School of Management and Director of the Laboratory for Financial Engineering, talk about the methods and economics for turning abandoned drug candidates into new therapies for patients. Annette and Andrew share the story of Gomekli, a formerly shelved Pfizer drug candida...
  • Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.
    Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D. 27.07.2026 54m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Aris Baras, M.D., SVP, Head of Regeneron Genetics Center (RGC) and Co-Head of Regeneron Genetic Medicines, talks about using large-scale human genetics to find better drug targets based on "superhuman" variants. Aris explains how multi-omics, linked health records, and AI are helping developers move faster in the clinic and reduce the odds of failure, while also pushing biotech toward ea...
  • Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
    Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D. 20.07.2026 56m
    We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the P...
  • BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
    BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin 13.07.2026 48m
    We love to hear from our listeners. Send us a message. On the Business of Biotech this week, industry veteran Dr. Jeremy Levin, Founder, Chairman, and former CEO at Ovid Therapeutics, sits down alongside the 2026 BIO Convention to talk about why public distrust and politicized institutions are putting the scientific enterprise at risk. We dig into what biotech leaders owe patients and the public, how innovation and capital can migrate out of the U.S., and what it takes to build biotech compa...
  • BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
    BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D. 06.07.2026 39m
    We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic in...

Popular in

The podcast also appears in the podcast charts of these countries.